Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  HIV Infection

  Free Subscription


Articles published in HIV Med

Retrieve available abstracts of 197 articles:
HTML format



Single Articles


    July 2025
  1. WYEN C, Sabranski M, Jonsson-Oldenbuttel C, Bogner J, et al
    Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany.
    HIV Med. 2025 Jul 4. doi: 10.1111/hiv.70061.
    PubMed     Abstract available


  2. BASIIMA J, Ssempijja V, Ndyanabo A, Bua GM, et al
    Retention outcomes during same-day antiretroviral therapy initiation in health facilities and outreach settings of Rakai, Uganda, 2016-2021.
    HIV Med. 2025 Jul 4. doi: 10.1111/hiv.70064.
    PubMed     Abstract available


  3. MENDES DE LEON KF, Moody K, Nellen JF, van Vugt M, et al
    Mode of administration matters: Willingness of people with HIV to switch to future long-acting treatments, and health care professionals' intention to discuss these options.
    HIV Med. 2025 Jul 2. doi: 10.1111/hiv.70066.
    PubMed     Abstract available


  4. VINAY D, Jayaweera I, Bowman M, Wijeratne DTD, et al
    Patient-reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long-acting injections as antiretroviral therapy: A systematic review.
    HIV Med. 2025 Jul 2. doi: 10.1111/hiv.70058.
    PubMed     Abstract available


  5. RAMADAN HK, Salah AE, Mohamed ZR, Ayoub A, et al
    False-positive reactivity of fourth-generation HIV enzyme immunoassay caused by COVID-19 and other infections.
    HIV Med. 2025 Jul 1. doi: 10.1111/hiv.70069.
    PubMed     Abstract available


  6. MAZZITELLI M, Leoni D, Campagnolo E, Cozzolino C, et al
    Anal cancer screening in a cohort of women with HIV: Uptake and outcomes from a prospective study in Northern Italy.
    HIV Med. 2025 Jul 1. doi: 10.1111/hiv.70068.
    PubMed     Abstract available


    June 2025
  7. MAZZITELLI M, Trunfio M, Dube K, Lopez AM, et al
    Measuring HIV knowledge and attitudes in the health care setting: Italian results from an ECDC/EACS survey.
    HIV Med. 2025 Jun 26. doi: 10.1111/hiv.70067.
    PubMed     Abstract available


  8. GHOSN J, Chow J, Gandhi M, Gorgolas M, et al
    Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes.
    HIV Med. 2025 Jun 26. doi: 10.1111/hiv.70065.
    PubMed     Abstract available


  9. GHAZALI MI, Zaki RA, Danaee M
    Late diagnosis of human immunodeficiency virus (HIV) and its associated factors in Asian countries: A systematic review.
    HIV Med. 2025 Jun 25. doi: 10.1111/hiv.70046.
    PubMed     Abstract available


  10. REZENE F, Amoyaw B, Rodrigues M, Ofori S, et al
    Gender equality in leadership of HIV care cascade clinical trials: A methodological study.
    HIV Med. 2025 Jun 20. doi: 10.1111/hiv.70062.
    PubMed     Abstract available


  11. KAYA A, Benke D, Swan T, Breitschwerdt S, et al
    Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
    HIV Med. 2025 Jun 16. doi: 10.1111/hiv.70063.
    PubMed    


  12. RING K, Elias A, Devonald M, Smuk M, et al
    Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV.
    HIV Med. 2025 Jun 13. doi: 10.1111/hiv.70057.
    PubMed     Abstract available


  13. NILSSON J, Elvstam O, Sorstedt E, Wagner P, et al
    Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register-based study.
    HIV Med. 2025 Jun 12. doi: 10.1111/hiv.70059.
    PubMed     Abstract available


  14. DEBROY P, Pike F, Gawrieh S, Corey KE, et al
    Circulating fibroblast growth factor 21 and growth differentiation factor 15 are associated with severity of hepatic steatosis in people with HIV.
    HIV Med. 2025 Jun 11. doi: 10.1111/hiv.70060.
    PubMed     Abstract available


  15. OKHAI H, Baskaran A, Bukasa L, Peters H, et al
    Changes in characteristics and HIV-clinical outcomes of pregnant people living with HIV in the UK.
    HIV Med. 2025 Jun 10. doi: 10.1111/hiv.70056.
    PubMed     Abstract available


  16. BALLIF M, Correia da Silva Saude M, Haerry D, Stoeckle M, et al
    Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV: A feasibility survey.
    HIV Med. 2025 Jun 8. doi: 10.1111/hiv.70053.
    PubMed     Abstract available


  17. VACCARI LC, Ming DK, Hazell J, Hunter A, et al
    Causes of death in people living with HIV from a North London cohort between 2006 and 2023: A descriptive analysis.
    HIV Med. 2025 Jun 4. doi: 10.1111/hiv.70054.
    PubMed     Abstract available


  18. CHIU SC, Wei LC
    Enhancing sexually transmitted and blood-borne infection prevention in opioid-agonist therapy programmes: Lessons from a canadian pragmatic trial and implications for Taiwan.
    HIV Med. 2025 Jun 2. doi: 10.1111/hiv.70055.
    PubMed    


    May 2025
  19. DOUTRE M, Godin MP, Dmitriev I, Pena-Gralle AP, et al
    Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.
    HIV Med. 2025 May 28. doi: 10.1111/hiv.70051.
    PubMed     Abstract available


  20. RASHID I, Unger NR, Willis C, Dhippayom T, et al
    Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppres
    HIV Med. 2025 May 27. doi: 10.1111/hiv.70050.
    PubMed     Abstract available


  21. SAMANTHA PC, Eduardo PA, Adrian CO
    The silent crisis: Vertical HIV transmission and the struggle for antiretroviral access.
    HIV Med. 2025 May 26. doi: 10.1111/hiv.70052.
    PubMed     Abstract available


  22. KOKORELIAS KM, Valentine D, Eaton AD, Dove E, et al
    "They didn't think we'd live this long": A qualitative exploration of older adults living with HIV perspectives on geriatric care in Ontario.
    HIV Med. 2025 May 22. doi: 10.1111/hiv.70047.
    PubMed     Abstract available


  23. CARTIER A, Milinkovic A, Goodall L, Mora-Peris B, et al
    HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70045.
    PubMed     Abstract available


  24. DIRAJLAL-FARGO S, Nyathi M, Sun S, Bonner LB, et al
    Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)-Heart study.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70049.
    PubMed     Abstract available


  25. FREER GB, Cooper J, Nirantharakumar K, Thomas GN, et al
    Trends in prevalence of anaemia among people living with HIV in the UK: 20 cross-sectional analyses using population-based electronic primary healthcare records.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70044.
    PubMed     Abstract available


  26. MENDEZ-LOPEZ A, Burns F, Sullivan A, Deogan C, et al
    Knowledge about biomedical HIV prevention among healthcare workers: A cross-sectional study in Europe and Central Asia.
    HIV Med. 2025 May 19. doi: 10.1111/hiv.70048.
    PubMed     Abstract available


  27. VAN BECKHOVEN D, Serrien B, Demeester R, Van Praet J, et al
    Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.
    HIV Med. 2025 May 12. doi: 10.1111/hiv.70027.
    PubMed     Abstract available


  28. SCHULZ-MEDINA SE, Tapia-Trejo D, Matias-Florentino M, Lopez-Sanchez DM, et al
    HIV molecular network in Mexico City (2021-2022): Understanding transmission dynamics through the role of newly diagnosed cases.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70029.
    PubMed     Abstract available


  29. JONES HT, Lynch L, Barber TJ, Rattue M, et al
    What services, interventions and support are available for People with HIV in England to manage their overall health and wellbeing? A scoping review.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70041.
    PubMed     Abstract available


  30. COTA MEDEIROS F, Mendez-Lopez A, Correia de Abreu R, Sarmento E Castro R, et al
    Knowledge and HIV-related stigma among Portuguese healthcare professionals: A cross-sectional analysis.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70039.
    PubMed     Abstract available


  31. ATALAY S, Mert K, Caglayan D, Sonmez U, et al
    Factors affecting treatment adherence in people with HIV - A single-Centre Descriptive Study from Turkey.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70042.
    PubMed     Abstract available


  32. POVSHEDNA T, Swann SA, Silva MAP, Tognazzini S, et al
    Self-reported HIV viral load is reliable and not affected by adverse lived experiences of women living with HIV in British Columbia.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70035.
    PubMed     Abstract available


  33. MENDES-FERREIRA AAC, Beber AMB, da Silveira LN, Guarabyra ASD, et al
    Assessment of compliance with recommendations for HIV perinatal transmission prevention, timely diagnosis and early treatment of children living with HIV in Brazil.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70038.
    PubMed     Abstract available


  34. LAPO-TALLEDO GJ, Zamora Cevallos AL, Arteaga Reyes CR, Sanchez Redroban JD, et al
    HIV disease hospitalizations and factors associated with in-hospital mortality in Ecuador: A nationwide analysis from 2015 to 2023.
    HIV Med. 2025 May 4. doi: 10.1111/hiv.70040.
    PubMed     Abstract available


  35. MOKADDAM M, Kronfli N, Sheehan NL, Gonzalez Reyes A, et al
    Antiretroviral therapy use, self-reported adherence, and viral suppression among women living with HIV in Canada.
    HIV Med. 2025 May 2. doi: 10.1111/hiv.70034.
    PubMed     Abstract available


  36. NAKAGAWA F, Palich R, Kall M, Sewell J, et al
    Impact of COVID-19 and factors associated with long COVID and COVID-19 vaccine uptake in people with HIV in the United Kingdom: Results from Positive Voices 2022.
    HIV Med. 2025 May 1. doi: 10.1111/hiv.70026.
    PubMed     Abstract available


  37. MAZZITELLI M, Petrara MR, Cozzolino C, Sasset L, et al
    Immune profiles and HIV reservoir in people switching to long-acting cabotegravir/rilpivirine: Findings from a real-life prospective study.
    HIV Med. 2025 May 1. doi: 10.1111/hiv.70030.
    PubMed     Abstract available


    April 2025
  38. DE VITO A, Tavelli A, Cozzi-Lepri A, Giacomelli A, et al
    Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort.
    HIV Med. 2025 Apr 28. doi: 10.1111/hiv.70037.
    PubMed     Abstract available


  39. QUISIAS J, Gill MJ, Coburn SB, Krentz HB, et al
    Cytomegalovirus serostatus among people with HIV, characterizing the prevalence, risk factors, and association with immune recovery.
    HIV Med. 2025 Apr 28. doi: 10.1111/hiv.70036.
    PubMed     Abstract available


  40. IRELAND AT, Ward J, Dolby H, Lawrence C, et al
    Using an automated decision support tool to improve HIV prescribing: A feasibility study.
    HIV Med. 2025 Apr 24. doi: 10.1111/hiv.70028.
    PubMed     Abstract available


  41. XIAO M, Shi Y, Lao Y, Ma Y, et al
    HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004-2023).
    HIV Med. 2025 Apr 19. doi: 10.1111/hiv.70033.
    PubMed     Abstract available



  42. Correction to "Perception of medical care among women living with HIV aged 40 years or older-a European-wide survey".
    HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70032.
    PubMed    


  43. ADMASSU Z, Logie CH, Vahedi L, Underhill A, et al
    Longitudinal associations between social determinants of health and well-being among women living with HIV in Canada: A latent class analysis.
    HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70031.
    PubMed     Abstract available


  44. BARDA B, Barilaro G, Bellini P, Turicchi G, et al
    Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.
    HIV Med. 2025 Apr 9. doi: 10.1111/hiv.70025.
    PubMed     Abstract available


  45. ZUBAIR A, Ahmad H, Arif MM, Ali M, et al
    mRNA vaccines against HIV: Hopes and challenges.
    HIV Med. 2025 Apr 7. doi: 10.1111/hiv.70024.
    PubMed     Abstract available


  46. ZHAO J, Gao M, Zhao D, Tian W, et al
    Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive systematic review and meta-analysis.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70023.
    PubMed     Abstract available


  47. CHACHU KH, Maboe KA
    Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70022.
    PubMed     Abstract available



  48. BHIVA Spring Conference 2025, 23 April - 25 April 2025, Brighton, UK.
    HIV Med. 2025;26 Suppl 2:17-137.
    PubMed    



  49. BHIVA Spring Conference 2025, 23 April - 25 April 2025, Brighton, UK.
    HIV Med. 2025;26 Suppl 2:3-16.
    PubMed    


    March 2025
  50. BARTOVSKA Z, Massmann R, Jilich D, Groh T, et al
    Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study.
    HIV Med. 2025 Mar 29. doi: 10.1111/hiv.70021.
    PubMed     Abstract available


  51. AKSAK-WAS B, Skonieczna-Zydecka K, Parczewski M, Hrynkiewicz R, et al
    Rethinking HIV treatment: How non-integrase strand regimens may hold the key to better immune health.
    HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
    PubMed     Abstract available


  52. MOSHI LS, Okuma J, Luoga E, Kalinjuma AV, et al
    Trends of severe HIV disease and mortality among children in rural Tanzania.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70015.
    PubMed     Abstract available


  53. SAUMOY M, Fernandez A, Tiraboschi J, Penafiel J, et al
    Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70017.
    PubMed     Abstract available


  54. VASELLI NM, Salaveria K, Winearls J, Garnham K, et al
    Pneumocystis jirovecii pneumonia-Immune reconstitution inflammatory syndrome: A review of published cases.
    HIV Med. 2025 Mar 24. doi: 10.1111/hiv.70016.
    PubMed     Abstract available


  55. MARTORELL C, Ramgopal M, Hagins D, Osiyemi O, et al
    Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
    HIV Med. 2025 Mar 21. doi: 10.1111/hiv.70018.
    PubMed     Abstract available


  56. PINCUS KJ, Faridi N, Ryscavage PA, Seung H, et al
    Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.
    HIV Med. 2025 Mar 20. doi: 10.1111/hiv.70019.
    PubMed     Abstract available


  57. HERNANDEZ-TRUJILLO PN, Lopez-Baron CA, Arevalo-Pinzon G, Trujillo-Guiza ML, et al
    Taxonomic and functional profile of the anorectal microbiota in HIV-positive and HIV-negative men who have sex with men, using a metagenomic approach.
    HIV Med. 2025 Mar 18. doi: 10.1111/hiv.70014.
    PubMed     Abstract available


  58. CHAWLA S, Kaida A, Brouillette MJ, Kleiner B, et al
    Impact of mental health service use on the HIV care cascade among women.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70008.
    PubMed     Abstract available


  59. SURIYARACHCHI DDC, Katuwavila NP
    Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.13770.
    PubMed     Abstract available


  60. HE X, Zheng W, Wang X, Jiang Y, et al
    Trend of HIV/AIDS disease burden in China from 1990 to 2021: An age-period-cohort model analysis.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70009.
    PubMed     Abstract available



  61. DOAK 2025 / 12th German-Austrian AIDS Congress, 20-22 March 2025, Hofburg Vienna.
    HIV Med. 2025;26 Suppl 1:3-82.
    PubMed    


    February 2025
  62. GIFFORD AJ, Jaspal R, Jones BA, McDermott DT, et al
    Predicting PrEP acceptability and self-efficacy among men who have sex with men in the UK: The roles of identity resilience, science mistrust, and stigma.
    HIV Med. 2025 Feb 27. doi: 10.1111/hiv.13768.
    PubMed     Abstract available


  63. HENDERSON M, Lyons D, Beddows S, Cowen M, et al
    High-risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.70001.
    PubMed     Abstract available


  64. BEGUELIN C, Surial B, Hofmann E, Begre L, et al
    Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.13766.
    PubMed     Abstract available


  65. BLANCH J, Martinez E, Mena A, Duenas C, et al
    Impact of training healthcare professionals in the detection and management of neuropsychiatric comorbidities in people with HIV: The CONECTAR project in Spain.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70002.
    PubMed     Abstract available


  66. ELKHEIR N, Dominic C, Price A, Carter J, et al
    HIV in Latin American migrants in the UK: A neglected population in the 95-95-95 targets.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70007.
    PubMed     Abstract available


  67. YU S, MacGibbon J, Bavinton B, Smith AKJ, et al
    Associations between country of birth, migration status and engagement in HIV care among gay and bisexual men living with HIV in Australia, 2019-2022.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.13769.
    PubMed     Abstract available


  68. AKASHANAND, Khatib MN, Serhan HA, Jena D, et al
    Spatial and temporal trends in HIV/AIDS burden among South Asian countries from 1990 to 2021: A systematic examination of the Global Burden of Disease study 2021.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.70003.
    PubMed     Abstract available


  69. MEDINA N, Alastruey-Izquierdo A, Bonilla O, Mercado D, et al
    Patients re-engaging with HIV care in Guatemala: Prioritizing CD4 counting and screening for histoplasmosis and tuberculosis.
    HIV Med. 2025 Feb 17. doi: 10.1111/hiv.70000.
    PubMed     Abstract available


  70. SADIQ E, Woodiwiss A, Tade G, Nel J, et al
    The role of atherosclerosis in HIV-associated vasculopathy in young South African stroke patients.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13764.
    PubMed     Abstract available


  71. NAZARENKO N, Chen YY, Borkowski P, Biavati L, et al
    Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13760.
    PubMed     Abstract available


  72. KUMAR S, Mehta R, Sah R, Verma A, et al
    Commentary on 'Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study'.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13767.
    PubMed    


  73. YANG Q, Zhou J, Lan G, Qin Q, et al
    Factors influencing the quality of life and social skills of children living with HIV: A case-control study.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13758.
    PubMed     Abstract available


  74. SALVO PF, Ciccullo A, Visconti E, Lombardi F, et al
    Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13765.
    PubMed     Abstract available


    January 2025
  75. PINAR SS, Manak M, Saravanan S, Imami N, et al
    Point-of-care nucleic acid testing - a step forward in controlling the HIV epidemic: A review.
    HIV Med. 2025 Jan 25. doi: 10.1111/hiv.13757.
    PubMed     Abstract available


  76. ODONGPINY EAL, Nicol M, Katana E, Owori J, et al
    A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda.
    HIV Med. 2025 Jan 24. doi: 10.1111/hiv.13761.
    PubMed     Abstract available


  77. IZQUIERDO R, Suarez-Garcia I, Marco-Sanchez C, Perez-Latorre L, et al
    Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
    HIV Med. 2025 Jan 21. doi: 10.1111/hiv.13762.
    PubMed     Abstract available


  78. MKHIZE N, Garrido J, Cole-Haley S, Diallo DD, et al
    Breaking down global barriers: A multinational and multi-community approach to combat stigma and enhance mental wellbeing in people with HIV.
    HIV Med. 2025 Jan 16. doi: 10.1111/hiv.13763.
    PubMed     Abstract available


  79. MCGARRITY MW, MacPherson P, Li A, Naccarato M, et al
    Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery.
    HIV Med. 2025 Jan 15. doi: 10.1111/hiv.13759.
    PubMed     Abstract available


  80. WALKER SH, Grierson J, Sullivan A, Alagaratnam J, et al
    The effects of the COVID-19 pandemic on people living with HIV.
    HIV Med. 2025 Jan 6. doi: 10.1111/hiv.13754.
    PubMed     Abstract available


  81. HU T, Yang S, Yu J, Yang Z, et al
    Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders.
    HIV Med. 2025 Jan 2. doi: 10.1111/hiv.13756.
    PubMed     Abstract available


    December 2024
  82. VARMA A, Singh MP, Sah S, Verma A, et al
    Commentary on 'DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy'.
    HIV Med. 2024 Dec 26. doi: 10.1111/hiv.13755.
    PubMed    


  83. SANDULESCU O, Moseholm E
    Editorial comment on: "It's like it's the old boys Club: The age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise".
    HIV Med. 2024 Dec 22. doi: 10.1111/hiv.13750.
    PubMed    


  84. OKHAI H, Winston A, Post F, Boffito M, et al
    Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study.
    HIV Med. 2024 Dec 19. doi: 10.1111/hiv.13753.
    PubMed     Abstract available


  85. MIRON VD, Sabin CA, Sandulescu O, Lourida G, et al
    Perception of medical care among women living with HIV aged 40 years or older-A European-wide survey.
    HIV Med. 2024 Dec 15. doi: 10.1111/hiv.13749.
    PubMed     Abstract available


  86. KOKORELIAS KM, Su E, Brown P, McKinlay S, et al
    "It's like it's the old boys club"-the age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise.
    HIV Med. 2024 Dec 12. doi: 10.1111/hiv.13751.
    PubMed     Abstract available


  87. BARRE T, Ramier C, Ory K, Sogni P, et al
    Transient CD4 cell recovery after hepatitis C virus cure in HIV/hepatitis C virus coinfected patients (ANRS CO13 HEPAVIH cohort).
    HIV Med. 2024 Dec 11. doi: 10.1111/hiv.13752.
    PubMed    


  88. ALFORD K, Sidat S, Bristowe K, Cicconi P, et al
    Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13748.
    PubMed     Abstract available


  89. FALCI DR, Pasqualotto AC, Vieceli T, Sued O, et al
    Performance of urine Xpert MTB/RIF ultra in a tuberculosis screening strategy in hospitalized patients with advanced HIV disease: Results from an implementation initiative in Brazil.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13746.
    PubMed     Abstract available


  90. SZETELA B, Bozejko M, Szymczak A, Giniewicz K, et al
    Rapid HIV pre-exposure prophylaxis (PrEP) initiation is safe and feasible: Experience from Wroclaw All Saints cohort in Poland 2017-2021.
    HIV Med. 2024 Dec 5. doi: 10.1111/hiv.13747.
    PubMed     Abstract available


  91. D'ARMINIO MONFORTE A, Tavelli A, Quiros-Roldan E, Fabbiani M, et al
    Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naive and ART-experienced people with HIV in real-world setting: Data from the Icona cohort.
    HIV Med. 2024 Dec 2. doi: 10.1111/hiv.13740.
    PubMed     Abstract available


  92. NELSON M, Bracchi M, Hunter E, Ong E, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non-tuberculous mycobacteria 2024.
    HIV Med. 2024;25 Suppl 4:3-25.
    PubMed    


    November 2024
  93. OJUKWU E, Pashaei A, Maia JC, Omobhude OF, et al
    Impact of the COVID-19 pandemic on the HIV care continuum and associated factors in middle-income countries: A mixed-methods systematic review.
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13739.
    PubMed     Abstract available


  94. JONES HT, Barber TJ
    A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty: Editorial comment on: "We are fragile, but we are strong": Navigating Frailty and HIV in Aging Populations: Perspectives on Language, Stigma
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13736.
    PubMed    


  95. YU X, Kuo YF, Dike AA, Efejuku T, et al
    Trends and disparities in antiretroviral therapy prescription rates among US Medicare beneficiaries with HIV.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13745.
    PubMed     Abstract available


  96. BARBOSU CM, Avirvarei C, Manciuc C, Dye T, et al
    Stigma-associated attitudes and practices among Romanian clinical providers.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13742.
    PubMed     Abstract available


  97. BLANCO JR, Gonzalez-Baeza A, Martinez-Vicente A, Albendin-Iglesias H, et al
    Loneliness and social isolation in people with HIV aged >/=50 years. The No One Alone (NOA)-GeSIDA study conducted by the GeSIDA 12021 study group.
    HIV Med. 2024 Nov 22. doi: 10.1111/hiv.13743.
    PubMed     Abstract available


  98. PENNER J, Ombajo LA, Nkuranga J, Otieno E, et al
    High prevalence of osteoporosis among virally suppressed older people (>/=60 years) living with HIV.
    HIV Med. 2024 Nov 21. doi: 10.1111/hiv.13741.
    PubMed     Abstract available


  99. BAKEWELL N, Kanitkar T, Dissanayake O, Symonds M, et al
    Comparing short-term mortality between people with and without HIV admitted to the intensive care unit: A single-centre matched cohort study (2000-2019).
    HIV Med. 2024 Nov 20. doi: 10.1111/hiv.13737.
    PubMed     Abstract available


  100. METCALFE R, Fraser R, Trayner KMA, Glancy M, et al
    Rising mortality among people who inject drugs living with HIV in Scotland, UK: A 20-year retrospective cohort study.
    HIV Med. 2024 Nov 18. doi: 10.1111/hiv.13733.
    PubMed     Abstract available


  101. KENIYOPOULLOS R, Khawaja AA, Boffito M, Emerson M, et al
    In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors.
    HIV Med. 2024 Nov 15. doi: 10.1111/hiv.13738.
    PubMed     Abstract available


  102. BLAKEY EG, Fairhead CEL, Rodger AJ, Burns FM, et al
    Clinical staff attitudes towards opt-out consent for blood-borne virus screening in emergency departments in England.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13735.
    PubMed     Abstract available


  103. RODKJAER LO, Storgaard M, Schougaard LMV
    Implementation of patient-reported outcomes for people living with HIV: Insights from patients and healthcare providers in a Danish outpatient clinic.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13734.
    PubMed     Abstract available


  104. SEMPERE A, Gonzalez-Rioja X, Martinez E
    AI in medicine: No longer the future, but the present.
    HIV Med. 2024 Nov 11. doi: 10.1111/hiv.13732.
    PubMed    


  105. LAGUNO M, de Lazzari E, Berrocal L, Inciarte A, et al
    Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.
    HIV Med. 2024 Nov 7. doi: 10.1111/hiv.13730.
    PubMed     Abstract available


  106. ABGRALL S, Selinger-Leneman H, Lanoy E, Becker A, et al
    Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH).
    HIV Med. 2024 Nov 4. doi: 10.1111/hiv.13729.
    PubMed     Abstract available


    October 2024
  107. STEPHAN C, Spinner CD, Rieke A, Christensen S, et al
    Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
    HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728.
    PubMed     Abstract available


  108. WATERS L, Martinez E
    Cardiovascular prevention: Statins and beyond-A message from the editors of the special issue of HIV medicine.
    HIV Med. 2024 Oct 29. doi: 10.1111/hiv.13731.
    PubMed    


  109. HICKS WL, Khalil S, Burke FW, Ho MQ, et al
    Comparison of risk factors and mortality in veterans with HIV and those without HIV suffering first major acute cardiovascular events.
    HIV Med. 2024 Oct 27. doi: 10.1111/hiv.13724.
    PubMed     Abstract available


  110. IZQUIERDO R, Suarez-Garcia I, Gomez-Garcia T, Marco-Sanchez C, et al
    Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
    HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726.
    PubMed     Abstract available


  111. FERNANDES G, Chappell E, Goetghebuer T, Kahlert CR, et al
    HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey.
    HIV Med. 2024 Oct 23. doi: 10.1111/hiv.13723.
    PubMed     Abstract available


  112. FONSECA F, Avelino-Silva VI, Odoke W, van den Hombergh J, et al
    Are people with HIV at advanced disease stages being left behind? A global survey.
    HIV Med. 2024 Oct 18. doi: 10.1111/hiv.13725.
    PubMed     Abstract available


  113. CLAIR-SULLIVAN NS, Vera JH, Maddocks M, Harding R, et al
    'We are fragile, but we are strong': A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty.
    HIV Med. 2024 Oct 13. doi: 10.1111/hiv.13722.
    PubMed     Abstract available


  114. MA Y, Achiche S, Tu G, Vicente S, et al
    The first AI-based Chatbot to promote HIV self-management: A mixed methods usability study.
    HIV Med. 2024 Oct 10. doi: 10.1111/hiv.13720.
    PubMed     Abstract available


  115. ERON JJ, Ramgopal M, Osiyemi O, Mckellar M, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
    HIV Med. 2024 Oct 6. doi: 10.1111/hiv.13721.
    PubMed     Abstract available


  116. TRAYNER KMA, Palmateer NE, McAuley A, Yeung A, et al
    Examining trends in the incidence of HIV infection among people with a history of drug use to inform an outbreak investigation and response: A retrospective cohort study.
    HIV Med. 2024 Oct 4. doi: 10.1111/hiv.13712.
    PubMed     Abstract available


  117. PLATTEAU T, Herrijgers C, Barvaux V, Vanden Berghe W, et al
    Chemsex and its impact on gay and bisexual men who have sex with men: Findings from an online survey in Belgium.
    HIV Med. 2024 Oct 3. doi: 10.1111/hiv.13717.
    PubMed     Abstract available


    September 2024
  118. GUTIERREZ F
    "Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study".
    HIV Med. 2024 Sep 27. doi: 10.1111/hiv.13719.
    PubMed    


  119. NIMKAR S, Kinikar A, Mave V, Khol V, et al
    Long-term risk of mortality and loss to follow-up in children and adolescents on antiretroviral therapy in Asia.
    HIV Med. 2024 Sep 26. doi: 10.1111/hiv.13718.
    PubMed     Abstract available


  120. MENDES-FERREIRA AAC, Veras NMC, Pinho REGG, Pascom AR, et al
    HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil.
    HIV Med. 2024 Sep 25. doi: 10.1111/hiv.13714.
    PubMed     Abstract available


  121. NAZARETH J, Adebayo A, Fahad M, Karim H, et al
    Cardiovascular medication adherence testing in patients living with HIV: A single-centre observational study.
    HIV Med. 2024 Sep 24. doi: 10.1111/hiv.13715.
    PubMed     Abstract available


  122. MANYARA AM, Manyanga T, Burton A, Wilson H, et al
    Prevalence, factors and quality of life associated with frailty and pre-frailty in middle-aged and older adults living with HIV in Zimbabwe: A cross-sectional study.
    HIV Med. 2024 Sep 20. doi: 10.1111/hiv.13716.
    PubMed     Abstract available


  123. FAROOQ HZ, Whitton L, Mwendera C, Divall P, et al
    Virtual care pathways for people living with HIV: A mixed-methods systematic review.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13701.
    PubMed     Abstract available


  124. WOODS J, Sokhela S, Akpomiemie G, Bosch B, et al
    DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13711.
    PubMed     Abstract available


  125. DAY S, Rae C, McOwan A, Wilkins R, et al
    Patient evaluation of Klick, a technology-enabled, nurse-delivered HIV outpatient pathway.
    HIV Med. 2024 Sep 15. doi: 10.1111/hiv.13710.
    PubMed     Abstract available



  126. Correction to "Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis".
    HIV Med. 2024 Sep 11. doi: 10.1111/hiv.13713.
    PubMed    


  127. BARBER TJ, Clarke A, Fox A, Mackie NE, et al
    CROI 2024 BHIVA working group summary.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13705.
    PubMed     Abstract available


  128. YANG X, Shi F, Zhang H, Giang WA, et al
    Long COVID among people with HIV: A systematic review and meta-analysis.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13708.
    PubMed     Abstract available


  129. PINEIRO C, Policarpo S, Caldas C, Santos L, et al
    Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
    HIV Med. 2024 Sep 6. doi: 10.1111/hiv.13699.
    PubMed     Abstract available


  130. PREVOTEAU DU CLARY F, Majerholc C, Zucman D, Livrozet JM, et al
    Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the French national health insurance claims data base: The COCOVIH study.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13690.
    PubMed     Abstract available


  131. MCCALL KL, Cabral DL, Coghlan JF, Concepcion AM, et al
    Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13709.
    PubMed     Abstract available


  132. SHU Y, Zhang M, Li J, Deng X, et al
    Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort.
    HIV Med. 2024 Sep 2. doi: 10.1111/hiv.13707.
    PubMed     Abstract available


    August 2024
  133. KO S, Dominguez-Dominguez L, Ottaway Z, Campbell L, et al
    Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom.
    HIV Med. 2024 Aug 29. doi: 10.1111/hiv.13706.
    PubMed     Abstract available


  134. URSENBACH A, Sireyjol A, Delpierre C, Duvivier C, et al
    Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study.
    HIV Med. 2024 Aug 28. doi: 10.1111/hiv.13698.
    PubMed     Abstract available


  135. LI N, Thomas L, Allan A, John B, et al
    Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV services.
    HIV Med. 2024 Aug 26. doi: 10.1111/hiv.13704.
    PubMed     Abstract available


  136. HSU RK, Brunet L, Lackey PC, Pierone G Jr, et al
    Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13700.
    PubMed     Abstract available


  137. GRINSPOON SK, Lu MT, Zanni MV, Diggs MR, et al
    What have we learned from the REPRIEVE trial and where do we go from here?
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13703.
    PubMed    


  138. VASHISHT S, Thakur N, Kant S, Rai S, et al
    Assessment of targeted intervention programme under the National AIDS Control Program among men who have sex with men in India.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13702.
    PubMed     Abstract available


  139. SWIFT E, Upton G, Fitzpatrick C, Roberts J, et al
    Impact of omission of routine blood monitoring of stable patients living with HIV during the coronavirus pandemic.
    HIV Med. 2024 Aug 18. doi: 10.1111/hiv.13696.
    PubMed     Abstract available


  140. CHAN CK, Huang SS, Wong KH, Leung CC, et al
    No increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression.
    HIV Med. 2024 Aug 12. doi: 10.1111/hiv.13695.
    PubMed     Abstract available


  141. WHITE TM, Fuster-RuizdeApodaca MJ, Iniesta C, Prats-Silvestre C, et al
    Network analysis to prioritize issues for intervention to improve the health-related quality of life of people with HIV in Spain.
    HIV Med. 2024 Aug 10. doi: 10.1111/hiv.13693.
    PubMed     Abstract available


  142. BEKELE A, Ahmed I, Tefera F, Yimam JA, et al
    Incidence and predictors of attrition from HIV treatment among adults living with HIV in high-caseload facilities following implementation of universal test and treat strategy in Ethiopia: A prospective cohort study.
    HIV Med. 2024 Aug 6. doi: 10.1111/hiv.13691.
    PubMed     Abstract available


  143. SAH S, Verma A, Zahiruddin QS, Rustagi S, et al
    Commentary on 'Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)'.
    HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13689.
    PubMed    


  144. KABLAWI D, Milic J, Thomas T, Fotsing Tadjo T, et al
    Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV.
    HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13697.
    PubMed     Abstract available


    July 2024
  145. INESTROZA K, Hurtado V, Larson ME, Satish S, et al
    Characterizing heart failure and its subtypes in people living with HIV.
    HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13694.
    PubMed     Abstract available


  146. PIACENTINI D, Nicolini G, Bugana D, Piccolin G, et al
    Breastfeeding in women living with HIV in high-income countries: It's time to act.
    HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13692.
    PubMed    


  147. SCOFIELD D, Frisch M, Andersson M, Storgaard M, et al
    Psychosocial and sexual health among men with and without HIV who have sex with men: A cross-sectional nationwide study in Denmark.
    HIV Med. 2024 Jul 18. doi: 10.1111/hiv.13688.
    PubMed     Abstract available


  148. RUIZ-BILBAO S, Videla S, Pascual E, Soler M, et al
    Functional and structural neuroretinal disorders in HIV Controllers. Prospective cohort study.
    HIV Med. 2024 Jul 9. doi: 10.1111/hiv.13685.
    PubMed     Abstract available


  149. ZAJDMAN-FAITELSON D, Cardenas-Hernandez ML, Guzman-Bucio S, Camiro-Zuniga A, et al
    Clinicopathological concordance of mucocutaneous manifestations in people living with HIV: A cross-sectional study.
    HIV Med. 2024 Jul 8. doi: 10.1111/hiv.13686.
    PubMed     Abstract available


  150. VERMA A, Pant M, Khatib MN, Singh MP, et al
    Commentary on 'Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities'.
    HIV Med. 2024 Jul 2. doi: 10.1111/hiv.13687.
    PubMed    


    June 2024
  151. SIMOES D, Raben D, Moran AB, Imaz A, et al
    The HepHIV 2023 Madrid conference: A call to action for political leadership in reaching the sustainable development goals on earlier testing and linkage to care for HIV, viral hepatitis, and sexually transmitted infections.
    HIV Med. 2024 Jun 24. doi: 10.1111/hiv.13683.
    PubMed     Abstract available


  152. BARQUET-MUNOZ SA, Lopez-Morales RA, Stier EA, Mejorada-Pulido E, et al
    Prevalence of anal high-risk human papillomavirus (HR-HPV) types in people living with HIV and a history of cancer.
    HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13684.
    PubMed     Abstract available


  153. BASOULIS D, Mastrogianni E, Eliadi I, Papadopoulou M, et al
    HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.
    HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13681.
    PubMed     Abstract available


  154. LAM JO, Hou CE, Alexeeff S, Levine T, et al
    Clinically recognized sleep disorders in people living with HIV.
    HIV Med. 2024 Jun 18. doi: 10.1111/hiv.13682.
    PubMed     Abstract available


  155. RING K, Smuk M, Shongwe M, Okonta L, et al
    Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
    HIV Med. 2024 Jun 10. doi: 10.1111/hiv.13679.
    PubMed     Abstract available


  156. HUTCHINSON J, Neesgard B, Kowalska J, Grabmeier-Pfistershammer K, et al
    Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.
    HIV Med. 2024 Jun 5. doi: 10.1111/hiv.13662.
    PubMed     Abstract available


  157. MALAGNINO V, Cozzi-Lepri A, Svicher V, Girardi E, et al
    Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy.
    HIV Med. 2024 Jun 4. doi: 10.1111/hiv.13680.
    PubMed     Abstract available


  158. PASIN C, Nunez DG, Kusejko K, Hachfeld A, et al
    Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
    HIV Med. 2024 Jun 3. doi: 10.1111/hiv.13677.
    PubMed     Abstract available


    May 2024
  159. CHROMY D, Urban N, Bauer WM, Kreuter A, et al
    Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak.
    HIV Med. 2024 May 30. doi: 10.1111/hiv.13678.
    PubMed     Abstract available


  160. INGILIZ P, Lutz T, Schewe K, Baumgarten A, et al
    Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic.
    HIV Med. 2024 May 29. doi: 10.1111/hiv.13651.
    PubMed     Abstract available


  161. SCHMIDT AJ, Weatherburn P, Wang H, Lutz T, et al
    Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021.
    HIV Med. 2024 May 27. doi: 10.1111/hiv.13657.
    PubMed     Abstract available


  162. SZCZEPANSKI A, Klesiewicz K, Ankiersztejn-Bartczak M, Drozdz K, et al
    Voluntary counselling and testing points (VCTs) in Poland as a complementary and accessible alternative to public healthcare facilities: A comparative analysis of epidemiological data from the VCTs and the National Institute of Public Health NIH-Natio
    HIV Med. 2024 May 21. doi: 10.1111/hiv.13658.
    PubMed     Abstract available


  163. YANG X, Zhang G, Kang W, Guo J, et al
    Related barriers to using HIV pre-exposure prophylaxis among MSM: A multicentre cross-sectional survey.
    HIV Med. 2024 May 21. doi: 10.1111/hiv.13663.
    PubMed     Abstract available


  164. KATLAMA C, Bisshop F, Bogner J, Perez Elias MJ, et al
    Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
    HIV Med. 2024 May 17. doi: 10.1111/hiv.13643.
    PubMed     Abstract available


  165. LOGIE CH, Sokolovic N, Casale A, Ndung'u M, et al
    Clinical HIV outcome trajectories associated with a history of child protective service out-of-home care: Longitudinal cohort findings with women living with HIV in Canada.
    HIV Med. 2024 May 17. doi: 10.1111/hiv.13660.
    PubMed     Abstract available


  166. LUMBRERAS ARETA M, Migliorelli Falcone FE, Rudin C, Kahlert CR, et al
    Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study.
    HIV Med. 2024 May 16. doi: 10.1111/hiv.13652.
    PubMed     Abstract available


  167. BUSCA-ARENZANA C, Ortega-Gonzalez D, Diaz-Almiron M, Montes ML, et al
    Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
    HIV Med. 2024 May 15. doi: 10.1111/hiv.13659.
    PubMed     Abstract available


  168. NAKAMURA H, Yamamoto K
    Mpox in people with HIV: A narrative review.
    HIV Med. 2024 May 15. doi: 10.1111/hiv.13661.
    PubMed     Abstract available


  169. BROWN L, Sargent P, Islam M, Downie C, et al
    Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat.
    HIV Med. 2024 May 9. doi: 10.1111/hiv.13656.
    PubMed     Abstract available


  170. FINLAYSON-TRICK E, Tam C, Wang L, Dawydiuk N, et al
    Access to care and impact on HIV treatment interruptions during the COVID-19 pandemic among people living with HIV in British Columbia.
    HIV Med. 2024 May 9. doi: 10.1111/hiv.13654.
    PubMed     Abstract available


  171. MATACOTTA JJ, Tran D, Yoon S
    The prevalence of major depressive disorder in people with HIV: Results from the All of Us Research Program.
    HIV Med. 2024 May 7. doi: 10.1111/hiv.13653.
    PubMed     Abstract available


  172. OOSTERHOF P, de Zoete BGJA, Vanhommerig JW, Langebeek N, et al
    De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study.
    HIV Med. 2024 May 7. doi: 10.1111/hiv.13655.
    PubMed     Abstract available


  173. DOCKRELL DH, Breen R, Collini P, Lipman MCI, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of pulmonary opportunistic infections 2024.
    HIV Med. 2024;25 Suppl 2:3-37.
    PubMed    


  174. GREIG J, Bamford A, Chadwick D, Darley A, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: Considerations in pregnancy 2024.
    HIV Med. 2024;25 Suppl 3:3-19.
    PubMed    


    April 2024
  175. LLIBRE JM, Garcia F, Blanco JL, Pelaez EP, et al
    Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain.
    HIV Med. 2024 Apr 30. doi: 10.1111/hiv.13650.
    PubMed     Abstract available


  176. DINESHA TR, Boobalan J, Kumar CV, Manikandan P, et al
    HIV-1 low-level viraemia predicts virological failure in first-line and second-line ART-experienced individuals in India: A retrospective longitudinal study.
    HIV Med. 2024 Apr 25. doi: 10.1111/hiv.13641.
    PubMed     Abstract available


  177. BULLO M, Kierszenowicz T, Acosta MC, Rolon MJ, et al
    Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina.
    HIV Med. 2024 Apr 24. doi: 10.1111/hiv.13646.
    PubMed     Abstract available


  178. JOHN M, Williams L, Nolan G, Bonnett M, et al
    Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
    HIV Med. 2024 Apr 21. doi: 10.1111/hiv.13647.
    PubMed     Abstract available


  179. DEMA E, Peters H, Gilleece Y, Thorne C, et al
    Residential and healthcare mobility during pregnancy among women living with HIV in the UK, 2009-2019.
    HIV Med. 2024 Apr 10. doi: 10.1111/hiv.13648.
    PubMed     Abstract available


  180. OZHMEGOVA E, Lebedev A, Antonova A, Kuznetsova A, et al
    Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia.
    HIV Med. 2024 Apr 7. doi: 10.1111/hiv.13642.
    PubMed     Abstract available


  181. CALZA L, Giglia M, Colangeli V, Bon I, et al
    Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
    HIV Med. 2024 Apr 3. doi: 10.1111/hiv.13644.
    PubMed     Abstract available



  182. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:21-111.
    PubMed    



  183. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:3-16.
    PubMed    



  184. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:17-20.
    PubMed    


    March 2024
  185. LIU Y, Cheng Z, Xian Y, Liu X, et al
    Cascade analysis of awareness, willingness, uptake and adherence with regard to PrEP among young men who have sex with men (YMSM) in China: A comparison between students and non-students.
    HIV Med. 2024 Mar 27. doi: 10.1111/hiv.13639.
    PubMed     Abstract available


  186. OTTAWAY Z, Campbell L, Fox J, Burns F, et al
    HIV outcomes during the COVID-19 pandemic in people of Black ethnicities living with HIV in England.
    HIV Med. 2024 Mar 26. doi: 10.1111/hiv.13640.
    PubMed     Abstract available


  187. SAWRY S, Ayalew K, Maimela G, Briggs-Hagen M, et al
    Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    HIV Med. 2024 Mar 22. doi: 10.1111/hiv.13638.
    PubMed     Abstract available


  188. ZOU S, Chen Z, Tan Y, Tan M, et al
    Microbiomes detected by cerebrospinal fluid metagenomic next-generation sequencing among patients with and without HIV with suspected central nervous system infection.
    HIV Med. 2024 Mar 21. doi: 10.1111/hiv.13634.
    PubMed     Abstract available


  189. SOCIAS ME, Cui Z, Le Foll B, Lei J, et al
    Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial.
    HIV Med. 2024 Mar 20. doi: 10.1111/hiv.13636.
    PubMed     Abstract available


  190. JACOBS TG, Okemo D, Ssebagereka A, Mwehonge K, et al
    Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    HIV Med. 2024 Mar 18. doi: 10.1111/hiv.13635.
    PubMed     Abstract available


  191. DOU Y, Lu R, Su L, Lan K, et al
    Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    HIV Med. 2024 Mar 17. doi: 10.1111/hiv.13632.
    PubMed     Abstract available


  192. VIOLETTE LR, Thomas KK, Dorward J, Quame-Amaglo J, et al
    Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.
    HIV Med. 2024 Mar 15. doi: 10.1111/hiv.13633.
    PubMed     Abstract available


  193. ZHAO J, Zhang L, Li L, Xie X, et al
    Growth of infants delivered by mothers with HIV in Guangxi, China: An 18-month longitudinal follow-up study, 2015-2021.
    HIV Med. 2024 Mar 13. doi: 10.1111/hiv.13624.
    PubMed     Abstract available


  194. TAHA AM, Elrosasy A, Mahmoud AM, Saed SAA, et al
    The effect of HIV and mpox co-infection on clinical outcomes: Systematic review and meta-analysis.
    HIV Med. 2024 Mar 5. doi: 10.1111/hiv.13622.
    PubMed     Abstract available


  195. PALICH R, Rodger AJ, Nicholls EJ, Wright T, et al
    Experiences with health care services and HIV testing after sexual assault in cisgender gay, bisexual and other men who have sex with men and transgender people.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13629.
    PubMed     Abstract available


  196. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
    SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
    PubMed     Abstract available


  197. NOE S, Ivanova A, Johnsson-Oldenbuttel C, Schafer G, et al
    Immunological alterations with GLP-1 agonists in people living with HIV.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13631.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.